Skip to main content
Log in

Zusammenfassung des ESC Positionsdokuments „Krebsbehandlung und kardiovaskuläre Toxizität“

  • Topic
  • Published:
best practice onkologie Aims and scope

Zusammenfassung

Fortschritte in der Chemotherapie neoplastischer Erkrankungen haben einerseits das Leben der Patienten verlängert, anderseits aber auch dazu geführt, dass die Nebenwirkungen der onkologischen Therapie für die betroffenen Patienten realisiert wurden. Zu den häufigsten Nebenwirkungen zählen die kardiovaskulären Komplikationen, die akut oder oft auch erst nach vielen Jahren zu Herzerkrankungen und zum Tod eines Patienten führen. Die Kardioonkologie beschäftigt sich mit der Prävention, Diagnostik und Behandlung der durch die Krebstherapie verursachten kardiovaskulären Erkrankungen. Neben der Herzinsuffizienz durch myokardiale Dysfunktion (Kardiotoxizität) zählen die koronare Herzerkrankung (KHK), die Herzklappenerkrankungen sowie die ventrikulären Arrhythmien infolge QT-Verlängerungen zu den wichtigsten kardiovaskulären Folgeerkrankungen der zytostatischen Therapie. Zudem kann es zu arterieller Hypertonie, thrombembolischen Ereignissen, pulmonaler Hypertonie, Vaskulopathien und Perikardkomplikationen kommen. Grundsätzlich wird zur Minimierung der kardiovaskulären Nebenwirkung potenziell kardiotoxischer Therapieverfahren eine strikte Einstellung kardiovaskulärer Risikofaktoren gefordert. Patienten mit eingeschränkter linksventrikulärer Funktion sollten bereits vor kardiotoxischer Chemotherapie durch Echokardiographie identifiziert werden. Eine Therapie mit Betablockern und ACE-Hemmern kann auch bei asymptomatischen Patienten indiziert sein, um Auswirkungen der Chemotherapie auf die myokardiale Dysfunktion zu minimieren. Eine prophylaktische Gabe von ACE-Hemmern und Betablockern während anthrazyklinhaltiger Chemotherapie kann bei herzgesunden Patienten erwogen werden.

Abstract

The numbers of survivors of cancer have increased as a consequence of advances in chemotherapy; however, the side effects of cancer treatment have become increasingly more important. The most frequent side effects include cardiovascular complications, which can lead to acute and delayed morbidity and mortality, often many years later. The discipline of cardio-oncology deals with the prevention, diagnostics and treatment of cardiovascular diseases caused by cancer therapy. The most important cardiovascular side effects of cytostatic therapy are heart failure due to myocardial dysfunction (cardiotoxicity), coronary artery disease, valvular disease and ventricular arrhythmia as a result of QT extension. In addition, arterial hypertension, thromboembolic events, pulmonary hypertension, vasculopathy and pericardial complications can also occur. Fundamentally, a strict limitation of risk factors is necessary to minimize the cardiovascular side effects of potentially cardiotoxic therapeutic procedures. Patients with impaired left ventricular function should be identified by echocardiographic examination prior to cardiotoxic chemotherapy. Treatment with beta blockers and angiotensin-converting enzyme (ACE) inhibitors can also be indicated in asymptomatic patients in order to minimize the effects of chemotherapy on myocardial dysfunction. Prophylactic administration of ACE inhibitors and beta blockers during anthracycline chemotherapy can be considered in patients free of cardiac disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2

Literatur

  1. Zamorano JL, Lancellotti P, Rodriguez Muñoz D et al (2016) ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J 37(36):2768–2801

  2. Hershman DL, McBride RB, Eisenberger A et al (2008) Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B‑cell non-Hodgkin’s lymphoma. J Clin Oncol 26:3159–3165

    Article  CAS  PubMed  Google Scholar 

  3. Yusuf SW, Sami S, Daher IN (2011) Radiation-induced heart disease: a clinical update. Cardiol Res Pract. doi:10.4061/2011/317659

    Google Scholar 

  4. Hooning MJ, Botma A, Aleman BM et al (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 99:365–375

    Article  PubMed  Google Scholar 

  5. Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and aftercancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 15:1063–1093

    Article  PubMed  PubMed Central  Google Scholar 

  6. Negishi K, Negishi T, Hare JL et al (2013) Independent and incremental value of deformation indices for prediction of trastuzumab-induced cardiotoxicity. J Am Soc Echocardiogr 26:493–498

    Article  PubMed  Google Scholar 

  7. Chow EJ, Chen Y, Kremer LC et al (2015) Individual prediction of heart failure among childhood cancer survivors. J Clin Oncol 33:394–402

    Article  PubMed  Google Scholar 

  8. Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97:2869–2879

    Article  CAS  PubMed  Google Scholar 

  9. Curigliano G, Cardinale D, Dent S et al (2016) Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. CA Cancer J Clin 66(4):309–325

    Article  PubMed  Google Scholar 

  10. Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61:2355–2362

    Article  CAS  PubMed  Google Scholar 

  11. Frickhofen N, Beck FJ, Jung B et al (2002) Capecitabine can induce acute coronary syndrome similar to 5‑fluorouracil. Ann Oncol 13:797–801

    Article  CAS  PubMed  Google Scholar 

  12. Aleman BM, van den Belt-Dusebout AW, De Bruin ML et al (2007) Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 109:1878–1886

    Article  CAS  PubMed  Google Scholar 

  13. Prosnitz RG, Hubbs JL, Evans ES et al (2007) Prospective assessment of radiotherapy-associated cardiac toxicity in breast cancer patients: analysis of data 3 to 6 years after treatment. Cancer 110:1840–1850

    Article  PubMed  Google Scholar 

  14. Eftekhari M, Anbiaei R, Zamani H et al. (2015) Radiation-induced myocardial perfusion abnormalities in breast cancer patients following external beam radiation therapy. Asia Ocean J Nucl Med Biol 3(1):3–9.

  15. Malanca M, Cimadevilla C, Brochet E et al (2010) Radiotherapy-induced mitral stenosis: a three-dimensional perspective. J Am Soc Echocardiogr 23:108:e101–102

    Google Scholar 

  16. Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 53:2231–2247

    Article  CAS  PubMed  Google Scholar 

  17. Priori SG, Blomstrom-Lundqvist C, Mazzanti A et al (2015) ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015(36):2793–2867

    Article  Google Scholar 

  18. Milan A, Puglisi E, Ferrari L et al (2014) Arterial hypertension and cancer. Int J Cancer 134:2269–2277

    Article  CAS  PubMed  Google Scholar 

  19. Akl EA, Kahale L, Barba M et al (2014) Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 7:CD006650

    Google Scholar 

  20. Farge D, Debourdeau P, Beckers M et al (2013) International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 11(1):56–70 (Jan)

    Article  CAS  PubMed  Google Scholar 

  21. Montani D, Bergot E, Gunther S et al (2012) Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125:2128–2137

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to S. Achenbach.

Ethics declarations

Interessenkonflikt

J. Hoog und S. Achenbach geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Additional information

Dieser Beitrag ist zuerst erschienen in

Herz 2016 · 41:684–689. DOI 10.1007/s00059-016-4493-6

Online publiziert: 9. November 2016

Springer Medizin Verlag 2016

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Achenbach, S. Zusammenfassung des ESC Positionsdokuments „Krebsbehandlung und kardiovaskuläre Toxizität“. best practice onkologie 12, 264–270 (2017). https://doi.org/10.1007/s11654-017-0035-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11654-017-0035-9

Schlüsselwörter

Keywords

Navigation